Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Market Intelligence

Set Alert for Market Intelligence

Medicare Plans Are Discouraging Generics Use

An AAM-sponsored study by researcher Avalere Health has concluded that Medicare Part D policy changes have led to generics being placed on non-generic tiers 53% of the time in 2020, with generics placed on the ‘preferred generic’ Tier 1 just 10% of the time.

Policy Market Intelligence

Gemme Bemoans ‘State Of Emergency’ In France

French off-patent industry association Gemme has declared a “state of emergency” for French generics as it revealed industry data for 2019 pointing to weak growth. Meanwhile, Gemme says, the country’s biosimilars market is “dynamic” and growing quickly but is still under-performing.

Market Intelligence France

UK Nefopam Prices Continue To Cause Pain

Continuing UK price rises were seen for nefopam in January, according to the latest figures from market researcher WaveData.

Market Intelligence United Kingdom

Post-Brexit Divergence Would Harm UK Industry

On the eve of the UK’s formal exit from the EU on 31 January, BGMA director general Warwick Smith has insisted that it is essential for the UK to stay as close as possible to the current European medicines framework following the conclusion of a transition period that is currently due to expire at the end of 2020.

Brexit Regulation

UK Imipramine Prices Double In December

December brought price rises for the UK generics market that included imipramine prices as much as doubling and a leap of more than two-thirds in the average price of frovatriptan tablets.

Market Intelligence United Kingdom

Outlook Positive For Indian Firms In 2020

Indian companies should post “healthy” growth in 2020, helped by a robust domestic market and abating US pricing pressures, analysts say.

Market Intelligence Generic Drugs
See All